SIRT1 Activation Attenuates the Cardiac Dysfunction Induced by Endothelial Cell-Specific Deletion of CRIF1

Area of Science:

• Cardiovascular Biology
• Mitochondrial Function
• Endothelial Biology

Background:

• CRISPR-interacting factor 1 (CRIF1) is essential for mitochondrial function, including peptide synthesis and oxidative phosphorylation.
• Cardiomyocyte-specific CRIF1 deletion leads to impaired mitochondrial function and cardiomyopathy.
• The role of endothelial CRIF1 in cardiac function and its relationship with sirtuin 1 (SIRT1) remain unclear.

Purpose of the Study:

• To investigate the impact of endothelial cell-specific CRIF1 deletion on cardiac function.
• To determine if SIRT1 mediates the effects of endothelial CRIF1 on the heart.
• To evaluate the therapeutic potential of SIRT1 activation in endothelial dysfunction-induced cardiac issues.

Main Methods:

• Developed endothelial cell-specific CRIF1 deletion mouse models.
• Assessed cardiac function using heart-to-body weight ratio and left ventricular fractional shortening.
• Analyzed mitochondrial function, ATP levels, oxidative stress, inflammation, and SIRT1 expression in heart tissues.
• Administered the SIRT1 activator SRT1720 to assess its therapeutic effects.

Main Results:

• Endothelial CRIF1 deletion resulted in increased heart-to-body weight ratio, lethality, and severe cardiac dysfunction.
• Mitochondrial dysfunction, reduced ATP, inflammation, and oxidative stress were observed in CRIF1-deleted hearts, correlating with decreased SIRT1.
• SRT1720 treatment improved cardiac function, activated endothelial nitric oxide synthase, reduced oxidative stress and inflammation, and restored zonula occludens-1 levels.

Conclusions:

• Endothelial CRIF1 is crucial for maintaining cardiac function.
• Dysfunctional endothelial CRIF1 contributes to cardiac dysfunction, potentially via SIRT1 pathways.
• SIRT1 induction represents a promising therapeutic strategy for endothelial dysfunction-related cardiac problems.